Literature DB >> 10901285

Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes.

K Yoshii1, K Kobayashi, M Tsumuji, M Tani, N Shimada, K Chiba.   

Abstract

Studies to identify the cytochrome P450 (CYP) isoform(s) involved in chlorpromazine 7-hydroxylation were performed using human liver microsomes and cDNA-expressed human CYPs. The kinetics of chlorpromazine 7-hydroxylation in human liver microsomes showed a simple Michaelis-Menten behavior. The apparent Km and Vmax values were 3.4+/-1.0 microM and 200.5+/-83.7 pmol/min/mg, respectively. The chlorpromazine 7-hydroxylase activity in human liver microsomes showed good correlations with desipramine 2-hydroxylase activity (r = 0.763, p < 0.05), a marker activity for CYP2D6, and phenacetin O-deethylase activity (r = 0.638, p < 0.05), a marker activity for CYP1A2. Quinidine (an inhibitor of CYP2D6) completely inhibited while alpha-naphthoflavone (an inhibitor of CYP1A2) marginally inhibited the chlorpromazine 7-hydroxylase activity in a human liver microsomal sample showing high CYP2D6 activity. On the other hand, alpha-naphthoflavone inhibited the chlorpromazine 7-hydroxylase activity to 55-65% of control in a human liver microsomal sample showing low CYP2D6 activity. Among eleven cDNA-expressed CYPs studied, CYP2D6 and CYP1A2 exhibited significant activity for the chlorpromazine 7-hydroxylation. The Km values for the chlorpromazine 7-hydroxylation of both cDNA-expressed CYP2D6 and CYP1A2 were in agreement with the Km values of human liver microsomes. These results suggest that chlorpromazine 7-hydroxylation is catalyzed mainly by CYP2D6 and partially by CYP1A2.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10901285     DOI: 10.1016/s0024-3205(00)00613-5

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  15 in total

1.  Tales from the war on error: the art and science of curating QSAR data.

Authors:  Marvin Waldman; Robert Fraczkiewicz; Robert D Clark
Journal:  J Comput Aided Mol Des       Date:  2015-08-20       Impact factor: 3.686

2.  Chlorpromazine-induced hepatotoxicity during inflammation is mediated by TIRAP-dependent signaling pathway in mice.

Authors:  Adarsh Gandhi; Tao Guo; Pranav Shah; Bhagavatula Moorthy; Romi Ghose
Journal:  Toxicol Appl Pharmacol       Date:  2012-12-11       Impact factor: 4.219

3.  Development of HepG2-derived cells expressing cytochrome P450s for assessing metabolism-associated drug-induced liver toxicity.

Authors:  Jiekun Xuan; Si Chen; Baitang Ning; William H Tolleson; Lei Guo
Journal:  Chem Biol Interact       Date:  2015-10-22       Impact factor: 5.192

Review 4.  Complex Drug-Drug-Gene-Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives.

Authors:  Flavia Storelli; Caroline Samer; Jean-Luc Reny; Jules Desmeules; Youssef Daali
Journal:  Clin Pharmacokinet       Date:  2018-10       Impact factor: 6.447

5.  The in vitro metabolism of desglymidodrine, an active metabolite of prodrug midodrine by human liver microsomes.

Authors:  Masayuki Akimoto; Izumi Iida; Hiroki Itoga; Atsunori Miyata; Shizuko Kawahara; Yoshiro Kohno
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jul-Sep       Impact factor: 2.441

6.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

7.  Contribution of human cytochrome p-450 isoforms to the metabolism of the simplest phenothiazine neuroleptic promazine.

Authors:  Jacek Wójcikowski; Lydiane Pichard-Garcia; Patrick Maurel; Władysława A Daniel
Journal:  Br J Pharmacol       Date:  2003-04       Impact factor: 8.739

Review 8.  Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation.

Authors:  Chantal Schlatter; Sabin S Egger; Lydia Tchambaz; Stephan Krähenbühl
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 9.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 10.  Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?

Authors:  Marja-Liisa Dahl
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.